Role of lncRNA MGP202 in Modulating B Cell Dynamics and Its Implications in Ulcerative Colitis
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Runing Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy Medical Sciences and Peking Union Medical College, Beijing, Ch…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, RNA, Long Noncoding, MicroRNAs, B-Lymphocytes. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National High-Level Hospital Clinical Research Funding, National Key Clinical Specialty Construction Project.
Abstract (Originalsprache)
Background
The upregulation of long noncoding RNA (lncRNA) MGP202 in ulcerative colitis (UC) patients suggests its potential significance in the disease. Understanding its role in UC pathogenesis and its impact on B cell dynamics is crucial for diagnostic and therapeutic advancements.
Methods
We investigated the expression and function of MGP202 in UC patients by examining its localization in colon specimens, performing knockdown and overexpression experiments in Raji B cells, and evaluating its interaction with hsa-miR-5590-3p. Furthermore, we explored the downstream effect on interleukin-33 (IL-33) expression.
Results
We found elevated expression of MGP202 in UC patients compared to healthy controls. Knockdown of MGP202 impeded B cell proliferation, while overexpression enhanced it. Direct binding between MGP202 and hsa-miR-5590-3p was confirmed. IL-33 expression decreased with hsa-miR-5590-3p overexpression but increased with MGP202 overexpression. Increased IL-33 levels were detected in the colon mucosa of UC patients.
Conclusions
Our study reveals the upregulation of MGP202 in UC patients and its regulation of B cell proliferation through sponging hsa-miR-5590-3p and modulating IL-33 expression. These findings highlight MGP202 as a potential diagnostic and therapeutic target for UC, particularly in the context of B cell dynamics. Further investigations are warranted to evaluate clinical applicability and unravel additional mechanisms related to MGP202 modulation of B cell behavior in UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy Medical Sciences and Peking Union Medical College, Beijing, China.
- Key Laboratory of RNA biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
- Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China.
ORCID-Profile: Xiaoyin Bai, Hong Yang
Förderung
- National Natural Science Foundation of China
- National High-Level Hospital Clinical Research Funding
- National Key Clinical Specialty Construction Project
- Natural Science Foundation of Beijing Municipality
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Zhou, R., Bai, X., Zhang, D., Zhu, Y., Dong, X., Wu, M., Guo, M., Yang, L., Yang, H., & Qian, J. (2025). Role of lncRNA MGP202 in Modulating B Cell Dynamics and Its Implications in Ulcerative Colitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf176
Vancouver
Zhou R, Bai X, Zhang D, Zhu Y, Dong X, Wu M, et al. Role of lncRNA MGP202 in Modulating B Cell Dynamics and Its Implications in Ulcerative Colitis. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf176
BibTeX
@article{Zhou2025,
author = {Zhou, Runing and Bai, Xiaoyin and Zhang, Dongdong and Zhu, Yashu and Dong, Xuyang and Wu, Meixu and Guo, Mingyue and Yang, Liu and Yang, Hong and Qian, Jiaming},
title = {Role of lncRNA MGP202 in Modulating B Cell Dynamics and Its Implications in Ulcerative Colitis},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf176}
}
EUVIMED